Inovio Pharmaceuticals (INO) AI Stock Analysis

• Market Cap: $105.00M
• Dividend Yield: N/A
• Average Volume (3M): 1.24M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.40
• Revenue Growth: -10.36%
• EPS Growth: 42.36%
• Country: US
• Employees: 134
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.87
• Shares Outstanding: 53,571,674
• 10 Day Avg. Volume: 1,618,231
• 30 Day Avg. Volume: 1,236,946
• PEG Ratio: 0.01
• Price to Book (P/B): 0.73
• Price to Sales (P/S): 228.26
• P/FCF Ratio: -0.48
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 445.83
• Enterprise Value/Gross Profit: -60.89
• Enterprise Value/Ebitda: -0.77
• 1Y Price Target: $7.33
• Price Target Upside: 275.90% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.87
• Revenue Forecast (FY): $94.17K

• Rating: 43 Neutral
• Price Target: $2.00 ▲(2.56% Upside)

Inovio Pharmaceuticals' overall stock score is primarily impacted by its challenging financial performance, characterized by persistent losses and negative cash flows. Technical analysis indicates bearish momentum, and valuation metrics are weak due to ongoing losses. While the earnings call provided some positive developments, financial constraints remain a significant concern.

Positive Factors

BLA Submission for INO-3107

The BLA submission for INO-3107 is a critical milestone, potentially leading to FDA approval and commercialization, enhancing long-term revenue prospects.

Cost Management

Effective cost management through reduced operating expenses strengthens financial stability and extends cash runway, supporting ongoing R&D efforts.

Pipeline Advancements

Advancements in the DNA medicine pipeline indicate potential for future product offerings, expanding market opportunities and competitive positioning.

Negative Factors

Negative Cash Flow

Persistent negative cash flow highlights challenges in sustaining operations without external financing, impacting long-term financial health.

Increased Net Loss

Rising net losses exacerbate financial strain, limiting resources for R&D and commercialization efforts, potentially delaying growth initiatives.

Reduction in Cash Reserves

Decreased cash reserves limit financial flexibility, necessitating additional financing to sustain operations and support strategic initiatives.

Inovio Pharmaceuticals Business Overview & Revenue Model

Company Description

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company engages in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, such as head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, including recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); and Lassa fever. Its partners and collaborators include ApolloBio Corp., AstraZeneca, Beijing Advaccine Biotechnology Co., Ltd., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), Department of Defense (DoD), HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Ology Bioservices, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Thermo Fisher Scientific, University of Pennsylvania, Walter Reed Army Institute of Research, and The Wistar Institute. The company has an agreement with Richter-Helm BioLogics GmbH & Co. KG to support investigational DNA vaccine INO-4800 for COVID-19; and a partnership with International Vaccine Institute and Seoul National University Hospital. The company was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.

How the Company Makes Money

Inovio Pharmaceuticals generates revenue primarily through a combination of government grants, research collaborations, and funding from partnerships with larger pharmaceutical companies. The company also seeks to monetize its proprietary technology through licensing agreements, allowing other entities to utilize its DNA delivery platform for their own drug development. Revenue may also come from the advancement of its clinical trial programs, which can attract further investment as they progress. Additionally, Inovio may receive milestone payments and royalties from partners based on the success of products developed under collaborative agreements, contributing to its financial sustainability.

Inovio Pharmaceuticals Financial Statement Overview

Summary

Inovio Pharmaceuticals faces significant financial challenges, with persistent losses, negative cash flows, and no revenue growth. Despite a strong equity position, the company's reliance on financing and lack of profitability raise concerns about its financial health.

Income Statement

Inovio Pharmaceuticals exhibits a challenging financial position with consistent negative net income and EBIT over the years. The company shows no revenue growth and gross profit margins are negative, indicating cost management issues or insufficient revenue to cover costs. The absence of gross profit and negative EBIT margins reflect the company's ongoing struggle with profitability.

Balance Sheet

The balance sheet reveals a relatively stable equity position with stockholders' equity being significantly higher than total debt, resulting in a low debt-to-equity ratio. However, the company has been heavily reliant on equity financing, as indicated by the substantial stockholders' equity compared to total assets. Despite the strong equity base, the company has not converted this into profitability or growth.

Cash Flow

Cash flow analysis indicates a negative operating and free cash flow, showing difficulties in generating cash from operations. The company has relied on financing activities to sustain operations, which may not be sustainable long-term. The absence of positive free cash flow growth further highlights challenges in cash generation.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	182.34K	217.76K	832.01K	10.26M	1.77M	7.41M
Gross Profit	-1.34M	217.76K	832.01K	10.26M	1.77M	7.41M
EBITDA	-105.08M	-103.95M	-130.39M	-270.90M	-296.56M	-149.56M
Net Income	-108.09M	-107.25M	-135.12M	-279.82M	-303.66M	-166.41M
Balance Sheet
Total Assets	69.39B	113.20M	170.95M	348.53M	495.94M	539.77M
Cash, Cash Equivalents and Short-Term Investments	50.80B	94.11M	145.29M	253.00M	401.31M	411.64M
Total Debt	10.02B	11.87M	30.21M	32.07M	33.02M	39.05M
Total Liabilities	77.11B	44.69M	53.60M	126.17M	96.27M	78.63M
Stockholders Equity	-7.72B	68.50M	117.35M	222.36M	399.67M	461.14M
Cash Flow
Free Cash Flow	-20.88B	-104.56M	-124.69M	-217.18M	-216.94M	-179.50M
Operating Cash Flow	-20.88B	-104.08M	-124.37M	-216.22M	-215.71M	-177.98M
Investing Cash Flow	5.33B	104.07M	87.36M	109.59M	-175.34M	-58.80M
Financing Cash Flow	20.32M	51.48M	5.00M	81.84M	211.50M	465.28M

Inovio Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INO, the sentiment is Negative. The current price of 1.95 is below the 20-day moving average (MA) of 2.29, below the 50-day MA of 2.40, and below the 200-day MA of 2.00, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 34.85 is Neutral, neither overbought nor oversold. The STOCH value of 10.37 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INO.

Inovio Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ANIX	49 Neutral	$144.51M	―	-57.94%	―	―	11.78%
AGEN	45 Neutral	$150.66M	―	―	―	-33.41%	81.19%
INO	43 Neutral	$105.00M	―	-328.45%	―	-10.36%	42.36%
ONC	43 Neutral	―	―	―	―	―	―
ATOS	36 Underperform	$109.55M	-3.77	-41.66%	―	―	-9.42%
TIL	34 Underperform	$101.19M	―	-51.74%	―	―	29.72%

Inovio Pharmaceuticals Corporate Events

Inovio Pharmaceuticals Reports Q3 2025 Financial Results

Inovio Pharmaceuticals, a biotechnology company, is dedicated to developing and commercializing DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases. The company has recently announced its third-quarter 2025 financial results and significant business updates.

Inovio Pharmaceuticals’ Earnings Call Highlights Progress and Challenges

Inovio Pharmaceuticals’ recent earnings call conveyed a cautiously optimistic sentiment. The company showcased significant strides with the BLA submission for INO-3107, successful FDA inspections, and advancements in DNA medicine technology, indicating a promising future. However, concerns were raised regarding decreased cash reserves and potential competition, which could pose challenges ahead.

Inovio Pharmaceuticals Reports Q2 2025 Financial Progress

Inovio Pharmaceuticals is a biotechnology company specializing in the development and commercialization of DNA medicines aimed at treating HPV-related diseases, cancer, and infectious diseases. The company is recognized for its innovative approach using DNA plasmids and proprietary delivery devices.